


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Tarlatamamb for treating small-cell lung cancer that has progressed after platinum-based chemotherapy ID6617

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
1 1011011ul Gollouitoos	submit or appeal)
Company	General
Amgen (tarlatamab)	All Wales Therapeutics and Toxicology
,	Centre
Patient/carer groups	Allied Health Professionals Federation
Asthma and Lung UK	Board of Community Health Councils in
Black Health Agency for Equality	Wales
Cancer Black Care	 British National Formulary
Cancer Equality	 Care Quality Commission
European Lung Foundation	Department of Health - Northern Ireland
Independent Cancer Patients Voice	 Healthcare Improvement Scotland
Macmillan Cancer Support	Medicines and Healthcare products
Maggie's Centres	Regulatory Agency
Marie Curie	National Association of Primary Care
Oncogene Research	National Pharmacy Association
Roy Castle Lung Cancer Foundation	NHS Confederation
Ruth Strauss Foundation	NHS Wales Joint Commissioning
South Asian Health Foundation	Committee
Specialised Healthcare Alliance	Scottish Medicines Consortium
Tenovus Cancer Care	Welsh Government
UK Lung Cancer Coalition	Possible comparator companies
1144	Possible comparator companiesSandoz (oral topotecan)
Healthcare professional groups	• Sandoz (Grai topotecan)
Association of Anaesthetists Association of Conser Physicians	Relevant research groups
Association of Cancer Physicians Association of Pagairston, Nurse	Cochrane Lung Cancer Group
 Association of Respiratory Nurse Specialists 	Genomics England
Association of Surgeons of Great	Institute of Cancer Research
Britain and Ireland	MRC Clinical Trials Unit
British Geriatrics Society	National Institute for Health Research
British Institute of Radiology	
British Oncology Pharmacy	Associated Public Health groups
Association	Public Health Wales
British Psychosocial Oncology Society	UK Health Security Agency
British Society of Interventional	
Radiology	
British Thoracic Oncology Group	



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Thoracic Society British Transplantation Society Cancer Research UK Lung Cancer and Mesothelioma Clinical Expert Group Lung Cancer Nursing UK National Heart and Lung Institute NHS Blood and Transplant Primary Care Respiratory Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Pathologists Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society 	
OthersDepartment of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of tarlatamamb for treating small-cell lung cancer that has progressed after platinum-based chemotherapy ID6617 Issue date: November 2025



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.